HC Wainwright Reaffirms “Neutral” Rating for Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 127.48% from the stock’s previous close.

Several other equities research analysts also recently weighed in on SAGE. Robert W. Baird cut their price target on Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Thursday. Oppenheimer dropped their price objective on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a report on Thursday, April 18th. Mizuho dropped their price objective on Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. TD Cowen dropped their price objective on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Finally, Wedbush reiterated a “neutral” rating and issued a $24.00 price objective on shares of Sage Therapeutics in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $33.55.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $10.99 on Thursday. The stock’s 50-day moving average is $11.30 and its two-hundred day moving average is $16.92. Sage Therapeutics has a 1-year low of $9.73 and a 1-year high of $37.17. The company has a market cap of $661.38 million, a price-to-earnings ratio of -1.31 and a beta of 0.90.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The company had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter last year, the company earned ($2.46) EPS. Sage Therapeutics’s revenue for the quarter was up 139.4% compared to the same quarter last year. Equities research analysts anticipate that Sage Therapeutics will post -6.54 earnings per share for the current fiscal year.

Institutional Trading of Sage Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new stake in Sage Therapeutics during the 1st quarter worth approximately $127,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sage Therapeutics by 353.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 5,406 shares during the period. Virtu Financial LLC acquired a new stake in shares of Sage Therapeutics in the 1st quarter valued at approximately $187,000. Quest Partners LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter valued at approximately $261,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sage Therapeutics by 31.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,256 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 2,967 shares during the period. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.